New Global Alliance for Improvement of HIV Diagnostics
The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the African Society for Laboratory Medicine (ASLM) have joined with a number of global partners to launch the Diagnostics Access Initiative.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the African Society for Laboratory Medicine (ASLM) have joined with a number of global partners to launch the Diagnostics Access Initiative.
Partners in the Initiative, which calls for improving laboratory capacity so that all people living with HIV can be linked to effective HIV treatment services, include UNAIDS, the World Health Organization (WHO), the Clinton Health Access Initiative (CHAI), UNICEF, and the US President’s Emergency Plan for AIDS Relief (PEPFAR).
The initiative will advocate for greater funding for laboratory services and diagnostic tools and forge partnerships to close diagnostic access gaps.
For HIV treatment to be optimally effective, people accessing the treatment need to monitor their viral load frequently. Currently, very few high-burden countries routinely offer viral load testing. The Diagnostics Access Initiative will focus “urgent attention on the importance of developing new, affordable viral load and infant diagnosis technologies” said Dr. Tsehaynesh Messele, ASLM’s Chief Executive.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
